z-logo
Premium
The clinical outcome of autoimmune thrombocytopenic purpura patients is related to their T cell immunodeficiency
Author(s) -
GarciaSuarez J.,
Prieto A.,
Reyes E.,
Manzano E.,
Merino J. L.,
AlvarezMon M.
Publication year - 1993
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.1993.tb03102.x
Subject(s) - phytohaemagglutinin , t cell , immunology , medicine , splenectomy , t lymphocyte , immunodeficiency , thrombocytopenic purpura , platelet , autoimmune disease , lymphocyte , immune system , antibody , spleen
Summary. In this work we have furthered the understanding of the alterations of T lymphocytes from 29 patients with active autoimmune thrombocytopenic purpura (ATP) and the clinical significance of their lymphocytes. An increased percentage of in vivo activated (CD25+ and DR+) T lymphocytes was found in ATP patients with respect to that found in 22 healthy controls. The function of these T cells measured as the proliferative response to polyclonal mitogenic signals is heterogeneously impaired in ATP patients. T lymphocytes from 65·5% (19/29) of the ATP patients showed a decreased proliferative response to these mitogenic signals. This functional alteration is associated with a redistribution of the T cell compartment in these patients' peripheral blood since a significant decrease of CD4+ T lymphocytes was found. We have also found that the impairment of the T cell function is different in the diverse clinical situations of the disease. Those with stable, untreated disease showed a marked decrease in the T cell proliferative response to mitogens. Furthermore, those patients who did not respond either to steroids or to splenectomy showed significantly reduced T lymphocyte blastogenesis after phytohaemagglutinin (PHA) stimulation in comparison to that found in responding patients.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here